Canada· CA-DIN-02479664
HEMLIBRA
A emicizumab product containing emicizumab, registered in Canada by HOFFMANN-LA ROCHE LIMITED. The same ATC class is registered in 15 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Emicizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B02BX06 (emicizumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 10 of them publish a price we can compare per daily dose
Emicizumab · ATC B02BX06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of emicizumab costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Emicizumab · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1013.07
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- EMICIZUMAB
- Manufacturer
- HOFFMANN-LA ROCHE LIMITED
- Country
- Canada (CA)
- ATC code
- B02BX06
- ATC class
- Emicizumab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for emicizumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Emicizumab · interactions on record
4 records
- 1 severe
- 3 moderate
Most severe, free to view
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBAB02BD03severe
- Coagulation factor VIIIB02BD02moderate
- Coagulation factor VIIaB02BD08moderate
- Octocog alfaB02BD28moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Emicizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumHemlibra 150 mg/mlRoche Registration
- SwitzerlandHemlibra
- CzechiaHEMLIBRARoche Registration GmbH, Grenzach-Wyhlen
- Japanエミシズマブ（遺伝子組換え）中外製薬
- United StatesHemlibraGenentech, Inc.
- FinlandHemlibraAbacus Medicine A/S
- United KingdomHemlibra 105mg/0.7ml solution for injection vialsRoche Products Ltd
- ItalyHEMLIBRA*1 flaconcino SC 150 mg/ml 0,4 mlROCHE REGISTRATION GMBH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hemlibra
- Liechtenstein · Hemlibra
- Norway · Hemlibra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e95e5374-4e63-4098-9930-809c451c8095 GET /v1/drugs/e95e5374-4e63-4098-9930-809c451c8095?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02479664",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "B02BX06",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "97033",
"strengths": [
"150 MG"
],
"ahfs_class": null,
"substances": [
"EMICIZUMAB"
],
"product_categorization": null
}See everything about emicizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.